Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation. It is reversible.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** To reduce the rate of thrombotic cardiovascular events, in patients with a history of myocardial infarction (MI), with or without ST-segment elevation MI (STEMI), who have been treated with aspirin.
* **Secondary Prevention of Atherothrombotic Events:** In patients with ACS or established atherosclerotic cardiovascular disease at high risk for an ischemic event.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **Secondary Prevention (established ASCVD):** 60 mg orally twice daily.
* Consider continuing beyond 12 months if the risk of ischemic events is high and bleeding risk is low.
## Pediatric Dosing
The safety and efficacy of ticagrelor in pediatric patients have not been established.
## Dose Adjustments
No dose adjustments are required based on age, sex, or renal/hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known history of transient ischemic attack (TIA) or stroke.
* Hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bleeding (major and minor), bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses, increased creatinine.
* **Other:** Hypotension, confusion, dizziness, rash.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors/Inducers:** May alter ticagrelor exposure. Use with caution.
* **CYP3A4 Substrates:** Ticagrelor may increase plasma concentrations of some CYP3A4 substrates.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Concomitant use should be carefully considered.
* **Digoxin:** Ticagrelor can increase digoxin levels. Monitor digoxin levels.
* **Proton Pump Inhibitors (PPIs):** Concomitant use may reduce ticagrelor efficacy. Consider alternatives or intermittent use.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor renal function (creatinine) and electrolytes periodically.
* Monitor heart rate for bradycardia.
* Assess for signs of dyspnea.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor that is taken twice daily, unlike clopidogrel and prasugrel.
* The 180 mg loading dose is crucial for patients with ACS.
* Dyspnea is a common side effect but is usually transient and not indicative of underlying cardiac or pulmonary disease.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If possible, patients should continue treatment for the recommended duration.
* Due to its reversible binding, ticagrelor may be preferred in situations where platelet function needs to be rapidly restored, though data is limited.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
